Table 1.
Characteristics of patients enrolled in clinical studies of MSCs as a therapeutic intervention for COVID-19.
| Patient characteristics | All groups | Control groups | MSC groups |
|---|---|---|---|
| Total patients, n | 403 | 196 | 207 |
| Sex, male, % | 56.9 | 55.4 | 58.4 |
| Mean age, years (SD) | 58.4 (7.1) | 60.1 (5.3) | 56.7 (8.5) |
| COVID-19 severity, n (%) | |||
| Mild | 39 (9.7) | 19 (9.7) | 20 (9.7) |
| Moderate | 20 (5.0) | 10 (5.1) | 10 (4.8) |
| Severe | 251 (62.3) | 124 (63.3) | 127 (61.4) |
| Critical | 93 (23.1) | 43 (21.9) | 50 (24.2) |
| Co-morbidities, n (%) | |||
| Hypertension | 109 (27.0) | 60 (30.6) | 49 (23.7) |
| Diabetes | 70 (17.4) | 34 (17.3) | 36 (17.4) |
| Obesity | 16 (4.0) | 5 (2.6) | 11 (5.3) |
| Chronic obstructive pulmonary disease | 4 (1.0) | 1 (0.5) | 3 (1.4) |
| Coronary artery disease | 9 (2.2) | 6 (3.1) | 3 (1.4) |
| Congestive heart failure | 10 (2.5) | 6 (3.1) | 4 (1.9) |
| Chronic kidney failure | 7 (1.7) | 5 (2.6) | 2 (1.0) |
| Other* | 45 (11.2) | 26 (13.3) | 19 (9.2) |
| Mean follow up, days (range) | 27.7 (14-60) | 26.9 (14-60) | 28.8 (14-60) |
* Includes current smoker, ex-smoker, pre-diabetes, asthma, tuberculosis, chronic bronchitis, hemorrhagic cerebral infarction, coronary heart disease, and chronic atrial fibrillation